Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

An astonishing fact about the GLP-1 meds that are helping millions lose weight: Tirzepatide, the active ingredient in ...

The U.S. stock market sank from record heights as Wall Street sifted through mixed developments on everything from the ...

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for ...

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Get the latest S&P 500 healthcare stock winners & losers, major earnings beats, profit forecasts, and legal news for key companies.

Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.

Eli Lilly has once again delivered extraordinary financial results, powered by its highly successful diabetes and obesity treatments. The pharmaceutical giant's third-quarter performance has left ...